| scholarly article | Q13442814 |
| P2093 | author name string | R Gold | |
| M Subramanyam | |||
| A Chan | |||
| N von Ahsen | |||
| A Salmen | |||
| R Hoepner | |||
| T Plavina | |||
| G Kuesters | |||
| A K Trampe | |||
| P2860 | cites work | PML diagnostic criteria: consensus statement from the AAN Neuroinfectious Disease Section | Q30613846 |
| Risk of natalizumab-associated progressive multifocal leukoencephalopathy | Q34275329 | ||
| Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy. | Q34803324 | ||
| Changes to anti-JCV antibody levels in a Swedish national MS cohort | Q37267644 | ||
| Longitudinal JCV serology in multiple sclerosis patients preceding natalizumab-associated progressive multifocal leukoencephalopathy | Q42170814 | ||
| Anti-JC virus (JCV) antibody prevalence in the JCV Epidemiology in MS (JEMS) trial | Q42214743 | ||
| Anti-JC virus antibodies in a large German natalizumab-treated multiple sclerosis cohort | Q42648662 | ||
| Progressive multifocal leukoencephalopathy during fumarate monotherapy of psoriasis | Q43187497 | ||
| A second-generation ELISA (STRATIFY JCV™ DxSelect™) for detection of JC virus antibodies in human serum and plasma to support progressive multifocal leukoencephalopathy risk stratification | Q43471219 | ||
| PML risk stratification using anti-JCV antibody index and L-selectin. | Q48938768 | ||
| P304 | page(s) | 2055217316630008 | |
| P577 | publication date | 2016-01-01 | |
| P1433 | published in | Multiple sclerosis journal - experimental, translational and clinical | Q27726873 |
| P1476 | title | Longitudinal analyses of anti-JCV antibody index for risk assessment of progressive multifocal leukoencephalopathy | |
| P478 | volume | 2 |
Search more.